SenesTech, Inc. SNES
We have developed and are commercializing products for managing animal pest populations through fertility control and population management strategies. Our current products focus on rat and mouse populations, and are known as: ContraPest, Evolve Rat, and Evolve Mouse.
As far back as we can trace, rodents have been foes to mankind. Today, they remain one of the most resilient and economically destructive vertebrate pests on the planet. Rodents threaten human and animal health, food security, and infrastructure worldwide, and humanity has spent centuries attempting to mitigate the problems associated with their proliferation. Rodents pose threats to human and animal health, food security and infrastructure around the world, and humanity has spent centuries trying to mitigate the problems associated with these pests. Rodents are known to be reservoir hosts for at least 60 zoonotic diseases and the potential transmission of these diseases creates a global risk to public health and safety, as well as agriculture, affecting crops, livestock, stored grain, and farm workers. Diseases such as leptospirosis and salmonellosis directly impact reproductive efficiency in livestock, contaminate feed supplies, and increase liability exposure for agricultural operators.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $1.9M | $1.2M | $1.0M | $600.0K | $282.0K | $143.0K | $297.0K | $52.0K | $318.0K |
| Cost of revenue | $833.0K | $853.0K | $654.0K | $555.0K | $356.0K | $281.0K | $101.0K | $241.0K | $45.0K | — |
| Gross profit | $1.4M | $1.0M | $539.0K | $464.0K | $244.0K | $1.0K | $42.0K | $56.0K | $7.0K | $318.0K |
| R&D | $1.7M | $1.7M | $1.2M | $1.9M | $2.0M | $1.5M | $1.9M | $2.4M | $3.2M | $2.7M |
| SG&A | $6.2M | $5.5M | $7.0M | $8.3M | $7.2M | $6.4M | $8.4M | $9.5M | $9.1M | $8.1M |
| Total operating expenses | $7.9M | $7.3M | $8.3M | $10.1M | $9.2M | $7.9M | $10.3M | $11.9M | $12.3M | $10.8M |
| Operating income | -$6.5M | -$6.2M | -$7.7M | -$9.7M | -$8.9M | -$7.9M | -$10.3M | -$11.9M | -$12.3M | -$10.5M |
| Pre-tax income | -$6.4M | -$6.2M | — | — | — | — | — | — | — | — |
| Income tax | $0 | $0 | — | — | — | — | — | — | — | — |
| Net income | -$6.4M | -$6.2M | -$7.7M | -$9.7M | -$8.3M | -$8.4M | -$10.0M | -$11.9M | -$12.3M | -$10.8M |
| EPS, basic | -1.95 | -8.86 | -115.10 | -148.08 | -14.77 | — | — | — | — | — |
| EPS, diluted | -1.95 | -8.86 | -115.10 | -148.08 | -14.77 | -2.78 | -7.69 | -12.62 | -1.12 | -1.71 |
| Shares, diluted (wtd. avg.) | 3.3M | 697,974 | 66,986 | 65,473 | 559,591 | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.6M | $1.3M | $5.4M | $4.8M | $9.3M | $3.6M | $1.9M | $4.9M | $2.1M | $11.8M |
| Short-term investments | $994.0K | $0 | — | — | — | — | — | — | — | — |
| Receivables | $201.0K | $335.0K | $95.0K | $113.0K | $77.0K | $25.0K | $26.0K | $139.0K | $16.0K | $10.0K |
| Inventory | $994.0K | $794.0K | $795.0K | $853.0K | $1.0M | $945.0K | $1.2M | $1.3M | $540.0K | $57.0K |
| Total current assets | $10.1M | $2.8M | $6.7M | $6.1M | $10.6M | $4.8M | $3.5M | $6.7M | $7.9M | $12.2M |
| Property, plant and equipment | $410.0K | $407.0K | $388.0K | $294.0K | $334.0K | $538.0K | $738.0K | $1.1M | $1.5M | $631.0K |
| Total assets | $12.8M | $3.3M | $7.3M | $6.8M | $11.5M | $6.0M | $5.0M | $7.8M | $9.3M | $12.9M |
| Accounts payable | $183.0K | $215.0K | $150.0K | $540.0K | $333.0K | $404.0K | $265.0K | $173.0K | $391.0K | $351.0K |
| Short-term debt | — | — | — | $0 | $32.0K | $98.0K | $123.0K | $219.0K | $177.0K | $45.0K |
| Total current liabilities | $798.0K | $561.0K | $786.0K | $1.3M | $1.1M | $794.0K | $1.6M | $1.2M | $1.2M | $1.8M |
| Long-term debt | — | — | — | — | — | $673.0K | $137.0K | $261.0K | $591.0K | $138.0K |
| Total liabilities | $3.3M | $767.0K | $942.0K | $1.5M | $1.5M | $2.1M | $2.4M | $1.4M | $1.8M | $2.0M |
| Retained earnings | -$142.5M | -$136.1M | -$129.9M | -$122.2M | -$112.5M | -$104.2M | -$95.9M | -$85.8M | -$73.6M | -$61.3M |
| Total equity | $9.6M | $2.5M | $6.4M | $5.3M | $10.0M | $3.9M | $2.6M | $6.3M | $7.5M | $10.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.8M | -$6.0M | -$7.6M | -$8.6M | -$7.8M | -$7.1M | -$8.1M | -$9.1M | -$9.3M | -$6.7M |
| Depreciation and amortisation | $135.0K | $156.0K | $135.0K | $183.0K | $303.0K | — | — | — | — | — |
| Stock-based compensation | $264.0K | $326.0K | $555.0K | $711.0K | $765.0K | $645.0K | $873.0K | $3.4M | $3.7M | $3.4M |
| Capital expenditure | $138.0K | $84.0K | $149.0K | $174.0K | $100.0K | $114.0K | $71.0K | $239.0K | $898.0K | $57.0K |
| Investing cash flow | -$1.1M | -$56.0K | -$149.0K | -$170.0K | -$99.0K | -$67.0K | -$71.0K | $5.0M | -$5.9M | -$57.0K |
| Financing cash flow | $13.1M | $2.0M | $8.3M | $4.2M | $13.6M | $8.9M | $5.1M | $6.9M | $5.5M | $18.4M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-028349.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $318.0K | $52.0K | $297.0K | $143.0K | $282.0K | $600.0K | $1.0M | $1.2M | $1.9M | $2.2M |
| Gross profit | $318.0K | $7.0K | $56.0K | $42.0K | $1.0K | $244.0K | $464.0K | $539.0K | $1.0M | $1.4M |
| Net income | -$10.8M | -$12.3M | -$11.9M | -$10.0M | -$8.4M | -$8.3M | -$9.7M | -$7.7M | -$6.2M | -$6.4M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Results announced Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Results announced Item 2.02
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2870
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| CF | CF Industries Holdings, Inc. | $18.26B | 13.5x | 19.3% |
| MOS | MOSAIC CO | $5.67B | 10.5x | 8.4% |
| SMG | SCOTTS MIRACLE-GRO CO | $3.45B | 24.0x | -3.9% |
| UAN | CVR PARTNERS, LP | $1.33B | 13.4x | 15.4% |
| CBUS | Cibus, Inc. | $108.2M | — | -14.6% |
| AVD | AMERICAN VANGUARD CORP | $30.4M | — | -5.9% |
| BIOX | Bioceres Crop Solutions Corp. | — | — | -27.9% |
| EVGN | Evogene Ltd. | — | — | -30.9% |